Hangzhou Just Biotherapeutics develops antibody and recombinant protein therapeutics and a biomanufacturing/process development platform in partnership with Seattle-based Just Biotherapeutics Inc. The company focuses on therapies for oncology, genetic rare diseases and metabolic diseases. It employs nearly one hundred scientists and engineers across sites in Hangzhou and Boston and is led by founder and CEO Yining Zhao. HJB was founded in 2016 by former Amgen and Genentech executives in Hangzhou, China. The company intends to use the new funds to enhance R&D capabilities and accelerate clinical trials globally. Its platform aims to reduce cost and speed development while maintaining global quality standards.

Total raised

$35M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2018